Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pharmarise HoldingsTSE:2796 -0.61%50 Piotroski F-Score is 7 as of Jul. 21, 2026, which is 17% above its 10-year median of 6.00. GuruFocus rates TSE:2796 with a GF Score™ of 50/100 and a GF Value™ of 円608.01 (Modestly Undervalued). The stock has 10 warning signs investors should review. Among 646 Healthcare Providers & Services companies, Pharmarise Holdings ranks better than 88.7% on this metric.
Good Sign:
Piotroski F-Score is 7, indicates a very healthy situation.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Pharmarise Holdings has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.
The historical rank and industry rank for Pharmarise Holdings's Piotroski F-Score or its related term are showing as below:
TSE:2796'
s Piotroski F-Score Range Over the Past 10 Years
Min: 4 Med: 6 Max: 8
Current: 7
During the past 13 years, the highest Piotroski F-Score of Pharmarise Holdings was 8. The lowest was 4. And the median was 6.
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Pharmarise Holdings Piotroski F-Score Related Terms
Pharmarise Holdings Piotroski F-Score Historical Data
* Premium members only.
The historical data trend for Pharmarise Holdings's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, Pharmarise Holdings's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharmarise Holdings Piotroski F-Score vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Pharmarise Holdings's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where Pharmarise Holdings's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Pharmarise Holdings's current Net Income (TTM) was 114.
==> Positive ==> Score 1.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Pharmarise Holdings's return on assets of this year was 0.00357098. Pharmarise Holdings's return on assets of last year was -0.01244658.
==> This year is higher. ==> Score 1.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Pharmarise Holdings's gearing of this year was 0.31660578. Pharmarise Holdings's gearing of last year was 0.37394561.
==> This year is lower or equal to last year. ==> Score 1.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
Pharmarise Holdings's current ratio of this year was 0.93961456. Pharmarise Holdings's current ratio of last year was 1.10435435.
==> Last year's current ratio is higher ==> Score 0.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Pharmarise Holdings's number of shares in issue this year was 11.322. Pharmarise Holdings's number of shares in issue last year was 11.322.
==> There is smaller number of shares in issue this year, or the same. ==> Score 1.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Pharmarise Holdings's gross margin of this year was 0.13607722. Pharmarise Holdings's gross margin of last year was 0.14116332.
==> Last year's gross margin is higher ==> Score 0.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Pharmarise Holdings's asset turnover of this year was 2.17742138. Pharmarise Holdings's asset turnover of last year was 2.15383572.
==> This year's asset turnover is higher. ==> Score 1.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
1
+
1
+
1
+
1
+
1
+
0
+
1
+
0
+
1
=
7
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Pharmarise Holdings has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.
Pharmarise Holdings (TSE:2796) has a Piotroski F-Score of 7 as of Jul. 21, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Pharmarise Holdings and its competitors. This is 17% above median its historical median of 6.00. Over the past decade, Pharmarise Holdings' Piotroski F-Score has ranged from 4.00 to 8.00. According to the industry distribution chart, Pharmarise Holdings ranks #73 out of 646 companies in the Healthcare Providers & Services industry, placing it in the top 11.3%.
Is Pharmarise Holdings' Piotroski F-Score too high?
Pharmarise Holdings' current Piotroski F-Score of 7 is 17% above median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 4.00 to a high of 8.00. The Healthcare Providers & Services industry median Piotroski F-Score is 5.00. Pharmarise Holdings' value of 7 is 40% above this industry median. Based on the distribution chart, Pharmarise Holdings ranks #73 out of 646 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Pharmarise Holdings has a GF Score™ of 50/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pharmarise Holdings' Piotroski F-Score compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Pharmarise Holdings ranks #73 out of 646 companies for Piotroski F-Score. This places Pharmarise Holdings in the top 11% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 5.00. Pharmarise Holdings' value of 7 is 40% above this benchmark. Historically, Pharmarise Holdings' own Piotroski F-Score has ranged from 4.00 to 8.00 over the past decade. While the company's 10-year median is 6.00 vs. the industry median of 5.00, Pharmarise Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Healthcare Providers & Services company?
The median Piotroski F-Score among Healthcare Providers & Services companies is 5.00, based on 646 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pharmarise Holdings's current Piotroski F-Score of 7 is 40% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Pharmarise Holdings and its competitors. For the Healthcare Providers & Services industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharmarise Holdings's current Piotroski F-Score is 7, which is 17% above median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmarise Holdings stock overvalued right now?
Based on GuruFocus' analysis, Pharmarise Holdings (TSE:2796) is currently considered Modestly Undervalued. The stock's GF Value™ is 円608.01, compared to a current price of 円491.00 — trading 19.2% below its estimated fair value. The current Piotroski F-Score is 7, which is 17% above median its 10-year median of 6.00 and 40% above the Healthcare Providers & Services industry median of 5.00. Pharmarise Holdings' overall GF Score™ is 50/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Pharmarise Holdings (TSE:2796), the current Piotroski F-Score is 7 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharmarise Holdings (TSE:2796) Overvalued in 2026?
Based on GuruFocus' analysis, Pharmarise Holdings stock appears to be undervalued.
The current stock price of 円491.00 is trading 19.2% below its estimated GF Value™ of 円608.01.
GuruFocus considers Pharmarise Holdings to be Modestly Undervalued.
Key valuation signals for TSE:2796:
Piotroski F-Score: 7 (17% above median its 10-year median of 6.00)
GF Value™: 円608.01 vs. price of 円491.00 (19.2% below fair value)
Industry Position: 40% above the Healthcare Providers & Services median (#73 of 646)
No single metric tells the full story. See the TSE:2796 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharmarise Holdings Corp is engaged in the operation of dispensing pharmacies, which prescribe medicines to general patients based on the prescriptions issued by medical institutions. It is also engaged in the storage and management of medical examination records of patients on behalf of the medical institution.
50GF Score
Get the complete analysis for TSE:2796
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:2796 has been successfully added to your 
